Cancer: Still a contraindication for allergen immunotherapy? Specific immunotherapy and cancer

被引：3

作者：

El-Qutob, David ^{[1
]}

Letran, Antonio ^{[2
]}

Matheu, Victor ^{[3
]}

Fernandez-Caldas, Enrique ^{[4
,5
]}

机构：

[1] Univ Hosp La Plana, Allergy Unit, Vila Real, Spain

[2] Hosp HLA Jerez Puerta Sur, Allergy Unit, Cadiz, Spain

[3] Univ Hosp Canarias, Serv Allergol, Tenerife, Spain

[4] Inmunotek SL, Madrid, Spain

[5] Univ S Florida, Coll Med, Tampa, FL 33620 USA

来源：

WORLD ALLERGY ORGANIZATION JOURNAL | 2021年 / 14卷 / 10期

关键词：

Cancer; Neoplasm; Specific immunotherapy; Allergen; Contraindication; GRASS-POLLEN IMMUNOTHERAPY; REGULATORY T-CELLS; MALIGNANCY; EXPERIENCE; MECHANISMS; INDUCTION; DISEASES; IL-10; IGG4; IGE;

D O I：

10.1016/j.waojou.2021.100597

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Allergen immunotherapy (AIT) is currently more than 100 years old. It is considered an evidencebased efficacious immune therapeutical treatment. It is at this time the only causative treatment for allergic respiratory and venom allergic diseases. Though clinical indications for AIT are well established, clinical contraindications to AIT differ among several guidelines. Regarding malignant neoplasia, traditionally, it has been considered as a relative or absolute contraindication with the concern that AIT might stimulate tumour growth even though pathogenic impact of AIT in cancer is not well understood. Furthermore, this contraindication is often based on observational case series, or case reports, with little real evidence-based data. Therefore, should cancer still be contemplated as an absolute contraindication for AIT? Keywords: Cancer, Neoplasm, Specific immunotherapy, Allergen, Contraindication

引用

页数：4

共 50 条

[41] Local and Systemic Reactions in Allergen Specific Immunotherapy
Canitez, Yakup
Ozturk, Rifat Can
Sapan, Nihat
GUNCEL PEDIATRI-JOURNAL OF CURRENT PEDIATRICS, 2007, 5 (03): : 92 - 95
[42] Regulatory environment for allergen-specific immunotherapy
Kaul, S.
May, S.
Luettkopf, D.
Vieths, S.
ALLERGY, 2011, 66 (06) : 753 - 764
[43] T cell responses induced by allergen-specific immunotherapy
Maggi, E.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2010, 161 (01) : 10 - 18
[44] Potential roles of cellular factor in allergen-specific immunotherapy
Apoil, P. A.
REVUE FRANCAISE D ALLERGOLOGIE, 2019, 59 (03): : 143 - 145
[45] Successful Allergen-Specific Immunotherapy: Induction of Unresponsiveness by 'Vaccination'
Bachmann, Martin F.
Vogel, Monique
Speiser, Daniel E.
VACCINES, 2023, 11 (12)
[46] Predicting Success of Allergen-Specific Immunotherapy
Zissler, Ulrich M.
Schmidt-Weber, Carsten B.
FRONTIERS IN IMMUNOLOGY, 2020, 11
[47] DermAll nanomedicine for allergen-specific immunotherapy
Garaczi, Edina
Szabo, Kornelia
Francziszti, Laszlo
Csiszovszki, Zsolt
Lorincz, Orsolya
Toke, Eniko R.
Molnar, Levente
Bitai, Tamas
Janossy, Tamas
Bata-Csoergo, Zsuzsanna
Kemeny, Lajos
Lisziewicz, Julianna
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2013, 9 (08) : 1245 - 1254
[48] Cancer Immunotherapy
White, Richard L., Jr.
Amin, Asim
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 20 (03) : 531 - +
[49] CANCER IMMUNOTHERAPY
Quintin-Colonna, Francoise
Montier, Yves
Pere, Helene
Sandoval, Federico
Merillon, Nathalie
Freyburger, Ludovic
Adotevi, Olivier
Tartour, Eric
BULLETIN DE L ACADEMIE VETERINAIRE DE FRANCE, 2010, 163 (04): : 363 - U172
[50] Immunotherapy of cancer
Borghaei, Hossein
Smith, Mitchell R.
Campbell, Kerry S.
EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 625 (1-3) : 41 - 54

← 1 2 3 4 5 →